Savara Inc. (NASDAQ:SVRA - Get Free Report) hit a new 52-week low on Friday. The company traded as low as $4.00 and last traded at $4.4320, with a volume of 4,158,457 shares traded. The stock had previously closed at $5.21.
Analyst Ratings Changes
SVRA has been the topic of a number of recent research reports. Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a research note on Sunday, October 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research note on Thursday, October 15th. HC Wainwright started coverage on shares of Savara in a research report on Thursday, November 12th. They set a "buy" rating and a $10.00 target price for the company. Royal Bank Of Canada set a $10.00 target price on Savara in a research report on Wednesday, October 7th. Finally, Citigroup restated a "market outperform" rating on shares of Savara in a research note on Wednesday, October 7th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $10.29.
View Our Latest Research Report on Savara
Savara Stock Down 17.2%
The stock has a 50 day moving average of $4.88 and a 200-day moving average of $5.32. The company has a debt-to-equity ratio of 0.28, a quick ratio of 8.55 and a current ratio of 8.55. The firm has a market capitalization of $951.98 million, a P/E ratio of -7.17 and a beta of 0.32.
Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. Research analysts predict that Savara Inc. will post -0.68 earnings per share for the current fiscal year.
Institutional Trading of Savara
A number of hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC lifted its position in Savara by 842.8% in the third quarter. Sterling Capital Management LLC now owns 5,063 shares of the company's stock valued at $26,000 after purchasing an additional 4,526 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of Savara in the 1st quarter worth approximately $57,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Savara in the third quarter worth $54,000. Sequoia Financial Advisors LLC purchased a new position in shares of Savara during the second quarter valued at approximately $69,000. Finally, Quarry LP boosted its stake in Savara by 6,524.4% in the 3rd quarter. Quarry LP now owns 11,924 shares of the company's stock worth $62,000 after purchasing an additional 11,744 shares in the last quarter. Institutional investors own 87.93% of the company's stock.
About Savara
(
Get Free Report)
Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.